{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:56Z","timestamp":1760239856622,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.hoc.2020.07.005","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T07:07:59Z","timestamp":1601276879000},"page":"1115-1131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Options for Chemotherapy and Scoring Response and Relapse"],"prefix":"10.1016","volume":"34","author":[{"given":"Cindy","family":"Varga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakra","family":"Chaulagain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2020.07.005_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.hoc.2020.07.005_bib2","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2020.07.005_bib3","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2020.07.005_bib4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A\u00a0trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2020.07.005_bib6","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"9873","key":"10.1016\/j.hoc.2020.07.005_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.hoc.2020.07.005_bib8","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2020.07.005_bib9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2020.07.005_bib10","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.07.005_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1937-6448(08)00602-3","article-title":"Role of proteasomes in cellular regulation","volume":"267","author":"Konstantinova","year":"2008","journal-title":"Int Rev Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.hoc.2020.07.005_bib12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.11627","article-title":"Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease","volume":"93","author":"Wechalekar","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2020.07.005_bib14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","article-title":"Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.07.005_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.07.005_bib16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2020.07.005_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.07.005_bib18","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/archinte.1989.00390020080016","article-title":"Peripheral neuropathy as an early marker of AL amyloidosis","volume":"149","author":"Duston","year":"1989","journal-title":"Arch Intern Med"},{"issue":"22","key":"10.1016\/j.hoc.2020.07.005_bib20","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1182\/blood.V128.22.5813.5813","article-title":"Once weekly subcutaneous bortezomib, cyclophosphamide, and dexamethasone as induction therapy for all AL amyloidosis","volume":"128","author":"Abbas","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.07.005_bib21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.07.005_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/ejh.12877","article-title":"Carfilzomib-containing combinations as frontline therapy for multiple myeloma: a meta-analysis of 13 trials","volume":"98","author":"Sheng","year":"2017","journal-title":"Eur J Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2020.07.005_bib24","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.07.005_bib25","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.hoc.2020.07.005_bib26","doi-asserted-by":"crossref","first-page":"22325","DOI":"10.1074\/jbc.M709900200","article-title":"Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor","volume":"283","author":"Kirk","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.hoc.2020.07.005_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.07.005_bib28","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.3324\/haematol.2014.110395","article-title":"Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma","volume":"99","author":"Dytfeld","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2020.07.005_bib29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","article-title":"A\u00a0phase 2 single-center study of carfilzomib 56\u00a0mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma","volume":"124","author":"Lendvai","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.13296","article-title":"Phase Ib\/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma","volume":"169","author":"Mikhael","year":"2015","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.hoc.2020.07.005_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.07.005_bib32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"issue":"17","key":"10.1016\/j.hoc.2020.07.005_bib33","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.07.005_bib34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A\u00a0phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.07.005_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed\/refractory primary systemic AL amyloidosis (RRAL)","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.07.005_bib36","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2019-126023","article-title":"A\u00a0phase 1\/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis","volume":"134","author":"Sanchez","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.07.005_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2020.07.005_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.07.005_bib39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"issue":"7","key":"10.1016\/j.hoc.2020.07.005_bib40","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","article-title":"Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis","volume":"109","author":"Wechalekar","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone\u00a0+\/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2020.07.005_bib43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00277-008-0600-y","article-title":"Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide","volume":"88","author":"Palladini","year":"2009","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2020.07.005_bib44","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A\u00a0matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2020.07.005_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"9","key":"10.1016\/j.hoc.2020.07.005_bib46","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2020.07.005_bib47","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.07.005_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.07.005_bib51","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2020.07.005_bib52","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","article-title":"Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1\/2 dose-escalation study","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2020.07.005_bib53","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A\u00a0phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2020.07.005_bib54","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2020.07.005_bib55","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.07.005_bib56","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2020.07.005_bib57","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A\u00a0phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.07.005_bib58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.hoc.2020.07.005_bib59","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting Bcl-2 for the treatment of multiple myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.07.005_bib60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","article-title":"Venetoclax: a new wave in hematooncology","volume":"61","author":"Mihalyova","year":"2018","journal-title":"Exp Hematol"},{"issue":"22","key":"10.1016\/j.hoc.2020.07.005_bib61","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.07.005_bib62","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2020.07.005_bib63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12185-020-02857-2","article-title":"Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: less is more?","volume":"112","author":"Yip","year":"2020","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.07.005_bib64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13506129.2019.1615428","article-title":"Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)","volume":"26","author":"Ghilardi","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.hoc.2020.07.005_bib65","first-page":"1","article-title":"Rapid complete response to single-agent Bcl-2 inhibitor venetoclax in a heart-transplanted patient with triple refractory immunoglobulin light-chain amyloidosis","author":"Gran","year":"2020","journal-title":"Acta Haematol"},{"issue":"18","key":"10.1016\/j.hoc.2020.07.005_bib66","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.07.005_bib67","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.07.005_bib68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.07.005_bib69","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2020.07.005_bib70","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.07.005_bib71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.07.005_bib72","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.07.005_bib73","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"issue":"36","key":"10.1016\/j.hoc.2020.07.005_bib74","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:59Z","timestamp":1760184959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0889858820300824"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.07.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Options for Chemotherapy and Scoring Response and Relapse","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}